MARKET

MRK

MRK

Merck & Co
NYSE
127.99
+0.49
+0.38%
After Hours: 127.99 0 0.00% 19:58 06/18 EDT
OPEN
128.27
PREV CLOSE
127.50
HIGH
128.73
LOW
127.09
VOLUME
6.53M
TURNOVER
0
52 WEEK HIGH
133.10
52 WEEK LOW
97.23
MARKET CAP
324.17B
P/E (TTM)
143.47
1D
5D
1M
3M
1Y
5Y
Merck & Company (MRK) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Merck & Company (MRK – Research Report) The company’s shares closed yesterday at $127.99. The company also received a Buy from Goldman Sachs and Morgan Stanley. Chen is an analyst with an average return of -9.0%.
TipRanks · 11h ago
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
NASDAQ · 17h ago
Cracking The Code: Understanding Analyst Reviews For Merck & Co
Merck & Co (NYSE:MRK) underwent analysis by 10 analysts in the last quarter. Merck makes pharmaceutical products to treat several conditions. The company has an average 12-month price target of $141.3. The firm has a solid revenue growth rate of 8.89%.
Benzinga · 18h ago
More Of The Same Isn't Good Enough For Roche
Seeking Alpha · 19h ago
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Barron‘s · 22h ago
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Seeking Alpha · 1d ago
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Merck & Co makes pharmaceutical products to treat several conditions. The firm's immuno-oncology platform is growing as a major contributor to overall sales. Merck and Co is in the Pharmaceuticals industry. The company is experiencing a notable slowdown in sales growth.
Benzinga · 1d ago
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca received approval for its cancer drug Imfinzi combined with chemotherapy for endometrial cancer. On Monday, the FDA put BioNTech SE's experimental cancer drug study on partial clinical hold. Moderna and Merck are testing a combined immunotherapy and chemotherapy treatment for melanoma.
Benzinga · 1d ago
More
About MRK
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.

Webull offers Merck & Co Inc stock information, including NYSE: MRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRK stock methods without spending real money on the virtual paper trading platform.